Is complement good or bad for cancer patients? A new perspective on an old dilemma
- 30 June 2009
- journal article
- review article
- Published by Elsevier BV in Trends in Immunology
- Vol. 30 (6), 286-292
- https://doi.org/10.1016/j.it.2009.04.002
Abstract
No abstract availableThis publication has 76 references indexed in Scilit:
- The Role of Complement in Inflammatory Diseases From Behind the Scenes into the SpotlightThe American Journal of Pathology, 2007
- Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactorsMolecular Immunology, 2007
- Molecular viral oncology of hepatocellular carcinomaOncogene, 2003
- Epstein–Barr virus and oncogenesis: from latent genes to tumoursOncogene, 2003
- Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1Blood, 2003
- In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomasBlood, 2003
- Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acidClinical and Experimental Immunology, 2003
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian CancerThe New England Journal of Medicine, 2003
- Inflammation and cancerNature, 2002
- Rules for Making Human Tumor CellsThe New England Journal of Medicine, 2002